Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2015-10-22 (10 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: SENS-DE-BRETAGNE (35490), Ille-et-Vilaine
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL PHARMASENS : revenue, balance sheet and financial ratios
SELARL PHARMASENS is a French company
founded 10 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in SENS-DE-BRETAGNE (35490),
this company of category PME
shows in 2024 a net income positive of 83 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMASENS (SIREN 814322624)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
82 532 €
83 604 €
118 574 €
80 809 €
87 748 €
96 291 €
93 342 €
146 615 €
18 026 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, SELARL PHARMASENS generates positive net income of 83 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 18 k€ -> 83 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
82 532 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 61%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 54%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
60.527%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
54.139%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
695.274
385.318
284.807
214.684
167.329
132.432
99.654
78.501
60.527
Financial autonomy
11.177
18.283
24.097
28.773
33.605
37.637
43.999
48.727
54.139
Repayment capacity
None
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
60.532024
2022
2023
2024
Q1: 16.45
Med: 58.41
Q3: 154.59
Average-5 pts over 3 years
In 2024, the debt ratio of SELARL PHARMASENS (60.53) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
54.14%2024
2022
2023
2024
Q1: 28.92%
Med: 49.95%
Q3: 69.49%
Good+10 pts over 3 years
In 2024, the financial autonomy of SELARL PHARMASENS (54.1%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 198.73. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
198.732
Liquidity indicators evolution SELARL PHARMASENS
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
208.022
228.701
316.278
262.092
241.225
210.307
220.431
210.142
198.732
Interest coverage
None
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
198.732024
2022
2023
2024
Q1: 129.47
Med: 182.14
Q3: 260.79
Good
In 2024, the liquidity ratio of SELARL PHARMASENS (198.73) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Positioning of SELARL PHARMASENS in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of SELARL PHARMASENS is estimated at
1 152 207 €
(range 802 379€ - 1 723 768€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
802k€1152k€1723k€
1 152 207 €Range: 802 379€ - 1 723 768€
NAF 5 année 2024
Valuation method used
Net Income Multiple
82 532 €
×
14.0x
=1 152 208 €
Range: 802 379€ - 1 723 769€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMASENS with other companies in the same sector:
Frequently asked questions about SELARL PHARMASENS
What is the revenue of SELARL PHARMASENS ?
The revenue of SELARL PHARMASENS is not publicly disclosed (confidential accounts filed with INPI).
Is SELARL PHARMASENS profitable?
Yes, SELARL PHARMASENS generated a net profit of 83 k€ in 2024.
Where is the headquarters of SELARL PHARMASENS ?
The headquarters of SELARL PHARMASENS is located in SENS-DE-BRETAGNE (35490), in the department Ille-et-Vilaine.
Where to find the tax return of SELARL PHARMASENS ?
The tax return of SELARL PHARMASENS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMASENS operate?
SELARL PHARMASENS operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart